Jubereq

Denosumab, the active ingredient in Jubereq, is a monoclonal antibody presented as a subcutaneous injection for use in bone‑related conditions. It works by inhibiting osteoclast activity, thereby reducing bone resorption in patients at high risk of fractures, such as postmenopausal women and individuals receiving glucocorticoids. Approved in the European Union for the treatment of osteoporosis and for preventing skeletal complications in cancer patients with bone metastases.

GNH USA supplies Jubereq as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Denosumab is indicated for conditions involving excessive bone resorption, primarily within the osteoporosis and oncology therapeutic areas.

- Postmenopausal osteoporosis: lowers incidence of vertebral, hip and non‑vertebral fractures. - Glucocorticoid‑induced bone loss: preserves bone mineral density and reduces fracture risk during long‑term steroid therapy. - Bone metastases‑related skeletal events: prevents pathological fractures, spinal cord compression and the need for radiation or surgery to bone.

Denosumab may be associated with a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Injection site reactions: pain, redness or swelling at the injection site. - Upper respiratory tract infection: nasopharyngitis or sinusitis. - Musculoskeletal pain: joint or muscle aches. - Dermatologic reactions: rash or eczema.

Serious or Rare Side Effects: - Hypocalcemia: low blood calcium levels, potentially symptomatic. - Osteonecrosis of the jaw (ONJ): exposed bone in the maxillofacial region. - Atypical femoral fractures: unusual fractures of the thigh bone with minimal trauma.

When prescribing Denosumab, clinicians should consider several safety and handling precautions.

- Calcium and vitamin D supplementation: ensure adequate intake to reduce hypocalcemia risk. - Renal impairment: monitor calcium levels closely in patients with severe kidney disease. - Dental procedures: perform invasive dental work before initiating therapy to lower ONJ risk. - Concomitant medications: avoid simultaneous use with other potent bone‑resorbing agents unless medically justified. - Pregnancy and lactation: contraindicated unless benefits outweigh potential risks; data are limited. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Denosumab can interact with other medicines, affecting calcium balance or bone health.

Major Interactions (Avoid): - Calcium supplements taken within 4 hours of injection: may interfere with absorption. - Bisphosphonates: concurrent use may increase risk of severe hypocalcemia. - Immunosuppressants (e.g., cyclosporine): may enhance infection risk.

Moderate Interactions (Monitor Closely): - Anticonvulsants (e.g., phenytoin, carbamazepine): can lower vitamin D levels, requiring monitoring. - Hormone replacement therapy: may affect bone turnover markers. - Chronic glucocorticoids: may require dose adjustment and closer calcium monitoring.